Quinupristin, an authoritative antibiotic employed for combating infections provoked by drug-resistant Gram-positive bacteria, showcases a notable therapeutic impact. By eliciting either bacteriostatic or bactericidal actions against susceptible strains, Quinupristin ensures efficacious administration tailored to tackle the challenges engendered by these resilient infections.
CAT No: R2069
CAS No:120138-50-3
Chemical Name:N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
Quinupristin is a semi-synthetic streptogramin antibiotic belonging to the streptogramin B class, widely recognized for its ability to inhibit bacterial protein synthesis. Derived from pristinamycin, it is frequently utilized in combination with dalfopristin to form the synergistic agent quinupristin/dalfopristin, although quinupristin alone retains significant value in biochemical and microbiological research contexts. Its molecular mechanism involves binding to the 50S ribosomal subunit, thereby disrupting peptide elongation and effectively halting bacterial growth. Due to its unique mode of action and resistance profile, quinupristin has become a valuable tool in studies of ribosomal function, antibiotic resistance mechanisms, and the development of novel antimicrobial agents.
Antibiotic mechanism research: As a potent inhibitor of bacterial protein synthesis, quinupristin is employed in laboratory studies to elucidate the detailed mechanisms by which streptogramins interact with the ribosome. Researchers utilize it to probe the conformational changes and functional dynamics of the 50S ribosomal subunit, gaining insight into translational control and the allosteric effects induced by antibiotic binding. Such studies are critical for understanding the molecular basis of antimicrobial activity and for informing the rational design of next-generation antibiotics targeting ribosomal machinery.
Antimicrobial resistance studies: The compound is frequently used as a reference molecule in investigations of bacterial resistance mechanisms, particularly in Gram-positive pathogens. By exposing bacterial cultures to quinupristin, scientists can select for and characterize resistance determinants, such as methyltransferases or efflux pumps, that diminish its efficacy. These experiments help to map genetic and biochemical pathways responsible for antibiotic resistance, facilitating the identification of novel targets for antimicrobial intervention and the development of diagnostic assays.
Microbial susceptibility testing: In microbiological laboratories, quinupristin serves as a standard agent in in vitro susceptibility assays to evaluate the sensitivity profiles of clinical and environmental bacterial isolates. Its inclusion in disk diffusion or broth microdilution protocols enables accurate assessment of resistance phenotypes and supports epidemiological surveillance of antimicrobial susceptibility patterns. This application is essential for validating new antimicrobial agents and for benchmarking the effectiveness of alternative therapeutic compounds in preclinical research.
Ribosome structural studies: The compound's specific binding properties make it a valuable probe in structural biology, particularly in X-ray crystallography and cryo-electron microscopy studies of the bacterial ribosome. By stabilizing ribosomal complexes in defined conformational states, quinupristin facilitates high-resolution mapping of antibiotic-ribosome interactions. These structural insights are instrumental in revealing the precise molecular contacts responsible for translational inhibition and in guiding the optimization of structurally related compounds.
Antibiotic synergy investigations: Quinupristin is also used in combination studies to explore synergistic effects with other protein synthesis inhibitors, most notably dalfopristin. Such experiments are designed to assess the cooperative inhibition of bacterial growth and to unravel the mechanistic basis for enhanced antimicrobial activity observed with dual-agent regimens. These synergy studies inform the development of combination therapies and contribute to the strategic management of multidrug-resistant bacterial infections in research settings.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More